IN2014MN01470A - - Google Patents

Info

Publication number
IN2014MN01470A
IN2014MN01470A IN1470MUN2014A IN2014MN01470A IN 2014MN01470 A IN2014MN01470 A IN 2014MN01470A IN 1470MUN2014 A IN1470MUN2014 A IN 1470MUN2014A IN 2014MN01470 A IN2014MN01470 A IN 2014MN01470A
Authority
IN
India
Prior art keywords
parathyroid hormone
human parathyroid
glutamate
lactate
stabilized aqueous
Prior art date
Application number
Inventor
Vaibhav Dnyaneshwar Deokar
DESHPANDE Anjali Deepak APTE
Sheetal Arvind Raut
Balaji Damodaran
Cyrus Karkaria
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1470MUN2014 priority Critical patent/IN2014MN01470A/en
Publication of IN2014MN01470A publication Critical patent/IN2014MN01470A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Stable pharmaceutical formulations comprising human parathyroid hormone are provided. The stabilized aqueous pharmaceutical formulation comprises human parathyroid hormone and a buffer selected from lactate or glutamate. In another embodiment a stabilized aqueous pharmaceutical formulation comprising human parathyroid hormone selected from the group of (1 34) (1 37) (1 38) (1 41) a buffer selected from lactate or glutamate a stabilizing agent and a parenterally acceptable preservative wherein the said formulation is sterile and ready for parenteral administration and having pH in the range of 3 to 7 is provided.
IN1470MUN2014 2012-01-20 2013-01-19 IN2014MN01470A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1470MUN2014 IN2014MN01470A (en) 2012-01-20 2013-01-19

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN53KO2012 2012-01-20
IN1470MUN2014 IN2014MN01470A (en) 2012-01-20 2013-01-19
PCT/IB2013/050503 WO2013108235A1 (en) 2012-01-20 2013-01-19 Stabilized pth formulation

Publications (1)

Publication Number Publication Date
IN2014MN01470A true IN2014MN01470A (en) 2015-04-17

Family

ID=47714479

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1470MUN2014 IN2014MN01470A (en) 2012-01-20 2013-01-19

Country Status (12)

Country Link
US (1) US20150011473A1 (en)
EP (1) EP2804622A1 (en)
JP (1) JP2015504087A (en)
AU (1) AU2013210689A1 (en)
BR (1) BR112014017424A8 (en)
CA (1) CA2862776A1 (en)
IN (1) IN2014MN01470A (en)
MX (1) MX2014008668A (en)
PH (1) PH12014501658A1 (en)
RU (1) RU2014133818A (en)
WO (1) WO2013108235A1 (en)
ZA (1) ZA201404918B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400423T1 (en) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Pth prodrugs
HUE063235T2 (en) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Delivery system for controlled release PTH compound
HUE070273T2 (en) 2016-09-29 2025-05-28 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
JP6577683B2 (en) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 Liquid pharmaceutical composition containing teriparatide having excellent stability
CA3075984C (en) * 2017-09-22 2024-10-01 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
JP2019060866A (en) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 Method for predicting biokinetics of liquid pharmaceutical composition
JP2019156805A (en) * 2018-03-16 2019-09-19 ナガセ医薬品株式会社 Container filling human pth(1-34) liquid pharmaceutical composition, and method for manufacturing the same
JP7399382B2 (en) * 2018-07-30 2023-12-18 武田薬品工業株式会社 Formulations to improve the stability of recombinant human parathyroid hormone
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN110917150A (en) * 2019-12-31 2020-03-27 北京博康健基因科技有限公司 PTH freeze-dried preparation and preparation method thereof
WO2021195877A1 (en) * 2020-03-30 2021-10-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same
WO2021229835A1 (en) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 Stable liquid pharmaceutical preparation containing teriparatide or salt thereof
JP6947946B1 (en) * 2020-05-11 2021-10-13 旭化成ファーマ株式会社 Stable liquid pharmaceutical product containing teriparatide or a salt thereof
TWI888383B (en) * 2020-06-19 2025-07-01 丹麥商阿森迪斯藥物骨疾病股份有限公司 Liquid pharmaceutical formulations of pth conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
ES2620326T3 (en) * 2004-08-24 2017-06-28 Kangawa, Kenji Liquid preparation of physiologically active peptide
KR100700869B1 (en) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Stable PTH Compositions Including PTH, Buffers, and Stabilizers
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins

Also Published As

Publication number Publication date
MX2014008668A (en) 2014-10-06
EP2804622A1 (en) 2014-11-26
WO2013108235A1 (en) 2013-07-25
AU2013210689A1 (en) 2014-07-31
CA2862776A1 (en) 2013-07-25
BR112014017424A8 (en) 2017-07-04
BR112014017424A2 (en) 2017-06-13
JP2015504087A (en) 2015-02-05
PH12014501658A1 (en) 2014-10-13
RU2014133818A (en) 2016-03-20
US20150011473A1 (en) 2015-01-08
ZA201404918B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
IN2014MN01470A (en)
PH12014502778B1 (en) Antibody formulation
PH12019500517A1 (en) Long-acting formulations of insulins
MX361590B (en) Topical delivery of skin compositions having low ph.
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2014011181A (en) Cyclodextrin-based microemulsions, and dermatological uses thereof.
IN2014MN02213A (en)
MX388963B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2016005395A (en) Stable formulation of insulin glulisine.
BR112013008601A8 (en) CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS
UA118576C2 (en) Pharmaceutical composition comprising brinzolamide
NZ702342A (en) Pharmaceutical formulation
MX355885B (en) Oral pharmaceutical composition.
JO3587B1 (en) Oral dosage forms of bendamustine
UA110792C2 (en) Pharmaceutical form bendamustine for oral use